The production line has the capacity to produce up to five million standard or anti-viral face masks per month, said the investment company.
Braveheart pointed out that conventional surgical type masks are recommended to be used for a maximum of two hours but P2F’s version contains an additional defensive layer that uses nanotechnology engineered to kill viruses and bacteria.
This additional active layer added to the three in standard masks is expected to improve the wearer's safety for prolonged use, said Braveheart.
Testing of the new nanotechnology material and specifically the time taken to kill viruses including the coronavirus (COVID-19) is currently underway at the University of Nottingham with results due from the start of October.
Providing the tests are successful, commercial manufacturing of the new masks is expected in early 2021.
In the event the tests produce an unsatisfactory result, P2F can use the production line to make produce conventional surgical type masks profitably, said Braveheart.